TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05613140

Intervention type: DRUG
Intervention: sacubitril/valsartan
Description: Two study cohorts were constructed to include adult HFrEF patients who newly initiated sacubitril/valsartan (Cohort 1) and adult CHF patients who newly initiated sacubitril/valsartan (Cohort 2).

Intervention type: DRUG
Intervention: sacubitril/valsartan
Description: Two study cohorts were constructed to include adult HFrEF patients who newly initiated sacubitril/valsartan (Cohort 1) and adult CHF patients who newly initiated sacubitril/valsartan (Cohort 2).
Study: NCT04928430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XAV-19
Description: 150 mg of XAV-19 single IV perfusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV infusion
Study: NCT06406842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebral oxygenation index guided hemodynamics management
Description: In the autoregulation group, anesthesiologist will maintain that the cerebral oxygen index value below 0.3. If cerebral oxygen index exceeds the threshold, norepinephrine or phenylephrine will be infused continuously, or arterial partial pressure of oxygen or arterial partial pressure of carbon dioxide will be adjusted to increase regional cerebral oxygen saturation.
Study: NCT05618834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Positive Care Interactions (PPCI)
Description: The PPCI consists of four steps: (1) stakeholder engagement in developing facility specific goals; (2) environment and policy assessments; (3) flexible staff education; and (4) ongoing mentorship, motivation, and support (in-person visits and text messages) for staff to optimize care interactions.~A research nurse facilitator (RNF), a registered nurse (RN) with prior experience in long-term care will work with an identified internal champion monthly to implement the four steps of PPCI. The PPCI intervention comprehensively focuses on intrapersonal, interpersonal, organizational, and environmental/policy factors to bring together evidence and key stakeholders to optimize daily care interactions in assisted living.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PPCI-Staff Education Only (EO)
Description: The EO will include a 30-45 min in-service session and monthly f/u visits for booster education. The education content and process will be the same as outlined in Step 3 of the PPCI for treatment sites.
Study: NCT05233332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-085
Description: 12mg BID HL-085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-085
Description: 12mg BID HL-085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-085
Description: 12mg BID HL-085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-085
Description: 12mg BID HL-085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 720mg BID Vemurafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 720mg BID Vemurafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 720mg BID Vemurafenib
Study: NCT05480410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: rTMS is a minimal invasive technique which focus on the M1 cortex. It can stimulate the cortex by depolarizing superficial neurons. For this study we will use a MagVenture MagPro R20
Study: NCT05939973

Intervention type: DEVICE
Group type: OTHER
Intervention: g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors
Description: The intent is to evaluate the safety and preliminary efficacy of a new Snowshoe suture placement pattern, POSE2.0 (sutures placed in the mid + distal body without fundus), with a moderate intensity diet and exercise program.
Study: NCT05182697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCI-210
Description: Oral CBD oil plus pills of CannAmide (palmitoylethanolamide (PEA) 400 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral CBD oil
Description: CBD- active CBD oil with twice daily CannAmide Placebo pills matched in appearance and taste to CannAmide active pill.
Study: NCT04837898

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Haskapa
Description: Haskapa Ltd, Oxford, UK

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: isocaloric to the haskap powder
Study: NCT05945797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4mg
Description: An injection of 4mg of dexamethasone will be given to patients approximately 2 to 4 hours prior to the procedure of ERCP.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone 4mg
Description: An injection of 4mg of dexamethasone will be given to patients approximately 2 to 4 hours prior to the procedure of ERCP.
Study: NCT05015907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: The nerve involved in the operation of Hickman catheter, chemoport, and Perm cath is the supraclavicular nerve. Therefore, it is judged that if only this nerve is selectively blocked, pain control can be effectively performed with a small amount of local anesthetic, and relatively few side effects occur.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (without intervention)
Description: No intervention
Study: NCT04383808

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Injected radiotracer with PET Insert
Description: 1. Informed consent will be obtained before beginning any study procedures.~2. Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pre-injected group with PET insert
Description: 1. Informed consent will be obtained before beginning any study procedures.~2. Participants who have received radiotracer for another PET imaging system. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed.
Study: NCT05060978

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Watch your Weight During the Holidays Program
Description: Participants in this group will have two video call individual sessions and one video call group session. This intervention will include self-monitoring strategies (self-weighing, diet monitoring and physical activity), and nutrition counseling and education. In addition, participants in this group will receive a weighing scale to achieve self-monitoring of body weight from the beginning of the study intervention until the end of the 52-weeks follow-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relative 5:2 Fasting
Description: Participants in this group will will have two video call individual sessions and one video call group session. This intervention will receive eating recommendations to follow a 5:2 intermittent fasting. They will be given low-calorie menus of 550 kcal and 660 kcal, for women and men respectively, which the participants in this group will apply on fasting days. The fasting will be held twice a week and on the remaining five days, the participants will not have any type of caloric restriction (it will be ad libitum). They will only have the general recommendation to adhere to a healthy dietary pattern.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Participants in this group will receive online information and a PDF file brochure during an individual video call session at the beginning of the 8-week period. This information will be about leading a healthy eating based on the norm for health promotion and education for healthy eating in Mexico (NOM-043-SSA2-2012).
Study: NCT06016673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants will receive intermittent theta burst stimulation (iTBS) to two brain areas, the right dorsolateral prefrontal cortex (rDLPFC) and the vertex.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants will receive intermittent theta burst stimulation (iTBS) to two brain areas, the right dorsolateral prefrontal cortex (rDLPFC) and the vertex.
Study: NCT05896878

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Root.Health Dietary Supplement
Description: The Root.Health supplement is composed of six plant-based compounds with established roles in supporting innate physiological processes which are implicated in pain: tetrohydrocurcumin, ergothioneine, dihydroberberine, trans-resveratrol, ginger root extract, and methylcobalamin. Participants will take the provided supplement twice per day for the entire study duration in addition to pain management treatment protocols the participants currently follow.
Study: NCT06472193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shanfield implantation technique in Mitroffanof procedure
Description: a stab incision of the bladder wall 1-2 cm above the trigone is deepened down to the mucosa without penetrating it. The prolapsed mucosa is grasped through this window and incised. The spatulated appendix-Mitrofanoff is advanced through the window to the interior of the bladder and its lower lip is anchored to the trigone 1-2 cm distal to the stab wound with an appropriate size (4/0-6/0) vicryle suture using a U-stich. The stitch passes initially through the bladder wall to its interior, looping full thickness through posterior lip of the appendix, then back through the full thickness of the bladder wall to be knotted outside. Supplementary stitches are added externally between the adventitia of the conduit and the detrusor to stabilise the tube-bladder intersection. The detrusorotomy is closed over loosely forming a short subdetrusor tunnel. This technique will be done by open lower midline incision or by laparoscopy using 3 or 4-port access.
Study: NCT06448559

Intervention type: OTHER
Intervention: Semi-directive interview
Description: Semi-directive interviews are individual interviews used in a qualitative approach to collect information in order to perform a thematic analysis

Intervention type: OTHER
Intervention: Semi-directive interview
Description: Semi-directive interviews are individual interviews used in a qualitative approach to collect information in order to perform a thematic analysis

Intervention type: OTHER
Intervention: Semi-directive interview
Description: Semi-directive interviews are individual interviews used in a qualitative approach to collect information in order to perform a thematic analysis
Study: NCT06514950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ujjayi Yogic Breathing
Description: Participants will undergo 6 weeks of resistive yogic breathing (Ujjayi) upon exhalation (first three weeks) and upon inhalation and exhalation (second three weeks).
Study: NCT04562870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Unit Dose Strength: 20 mg; Dose Formulation: Tablet; Dosage Level: 60 or 80 mg, QW; Route of Administration: Oral

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice Treatment
Description: Physician's choice treatment may include ruxolitinib retreatment, fedratinib, chemotherapy (e.g., hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulatory agent, androgen, interferon (all as per clinical practice) and may include supportive care only with no MF treatment; no investigational therapies are allowed.
Study: NCT06583980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Nurse-coordinated self-management support for people with inflammatory arthritis and substantial disease impact
Description: A coordinating rheumatology nurse who follows the participant for six months, goal setting and action planning with the nurse, opportunity for needs based support from a physiotherapist, an occupational therapist and a social worker, opportunity for interdisciplinary conferences to coordinate support to achieve the agreed upon goals and a final status consultation.
Study: NCT06584006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections
Description: Thymalfasin for injection 1.6mg subcutaneous injection once daily (qd) for 7 days, and Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Interleukin-2 Injections
Description: Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.
Study: NCT04774393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT06188637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod Oral Capsule
Description: open label ozanimod
Study: NCT05430178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral sugar tolerance test
Description: Measurement of glucose and insulin for calculation of insulin sensitivity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral sugar tolerance test
Description: Measurement of glucose and insulin for calculation of insulin sensitivity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral sugar tolerance test
Description: Measurement of glucose and insulin for calculation of insulin sensitivity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral sugar tolerance test
Description: Measurement of glucose and insulin for calculation of insulin sensitivity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De novo lipogenesis test
Description: Oral consumption of deuterated water to measure incorporation of label into lipids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De novo lipogenesis test
Description: Oral consumption of deuterated water to measure incorporation of label into lipids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De novo lipogenesis test
Description: Oral consumption of deuterated water to measure incorporation of label into lipids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De novo lipogenesis test
Description: Oral consumption of deuterated water to measure incorporation of label into lipids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluconeogenesis test
Description: Oral consumption of 13C-labeled glycerol to measure incorporation into glucose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluconeogenesis test
Description: Oral consumption of 13C-labeled glycerol to measure incorporation into glucose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluconeogenesis test
Description: Oral consumption of 13C-labeled glycerol to measure incorporation into glucose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluconeogenesis test
Description: Oral consumption of 13C-labeled glycerol to measure incorporation into glucose
Study: NCT06234761

Intervention type: DRUG
Intervention: Dupilumab
Description: Patient who start to take dupilumab will be followed. This study is only observational
Study: NCT05045586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The tunnel technique for root coverage with CTG without Cross-linked Hyaluronic Acid
Description: The tunnel technique for root coverage with CTG without Cross-linked Hyaluronic Acid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The tunnel technique for root coverage with CTG andCross-linked Hyaluronic Acid
Description: The tunnel technique for root coverage with CTG andCross-linked Hyaluronic Acid
Study: NCT06452563

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ketoanalogue supplementation
Description: This drug contains 5 essential amino acids (L-lysine monoacetate 75mg, L-threonine 53mg, L-tryptophan 23mg, L-histidine 38mg and L-tyrosine 30mg) and 5 essential amino acid substitutes in the form of calcium salts, including 4 keto-analogues (keto-isoleucine, keto-leucine, keto-valine, and keto-phenylalanine) and a hydroxy-analogue (hydro methionine) as calcium salt . The drug is approved by the Egyptian Drug Authority (EDA) with registration number 34677/2021

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ketoanalogue supplementation
Description: This drug contains 5 essential amino acids (L-lysine monoacetate 75mg, L-threonine 53mg, L-tryptophan 23mg, L-histidine 38mg and L-tyrosine 30mg) and 5 essential amino acid substitutes in the form of calcium salts, including 4 keto-analogues (keto-isoleucine, keto-leucine, keto-valine, and keto-phenylalanine) and a hydroxy-analogue (hydro methionine) as calcium salt . The drug is approved by the Egyptian Drug Authority (EDA) with registration number 34677/2021

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intradialytic exercise
Description: low-intensity exercise training composed of knee extension and hip abduction and flexion from a three-repetition maximum (3RM) using ankle weights

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intradialytic exercise
Description: low-intensity exercise training composed of knee extension and hip abduction and flexion from a three-repetition maximum (3RM) using ankle weights
Study: NCT05721456

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 12-Valent Pneumococcal Conjugate Vaccine
Description: PCV12 group 1: 550 subjects receiving the 12-valent pneumococcal polysaccharide conjugate vaccine (12Pn-PD-DiT-CRM), defined as PCV12 in this protocol

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-Valent Pneumococcal Conjugate Vaccine
Description: PCV12 group 1: 550 subjects receiving the 12-valent pneumococcal polysaccharide conjugate vaccine (12Pn-PD-DiT-CRM), defined as PCV12 in this protocol

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-Valent Pneumococcal Conjugate Vaccine
Description: PCV12 group 1: 550 subjects receiving the 12-valent pneumococcal polysaccharide conjugate vaccine (12Pn-PD-DiT-CRM), defined as PCV12 in this protocol
Study: NCT05626621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray
Description: Participants will follow this medication regimen for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Nasal Irrigation (1 mg capsule)
Description: Participants will follow this medication regimen for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation
Description: Participants will follow this medication regimen for 6 months.
Study: NCT06284265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raphamin
Description: Tablet for oral use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral use.
Study: NCT06235775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001 Placebo
Description: 0.9% normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001 1.12mg
Description: Lyophilized peptide from hTERT
Study: NCT05196152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MomMoodBooster
Description: MomMoodBooster is an empirically validated online intervention for perinatal women.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MomMoodBooster
Description: MomMoodBooster is an empirically validated online intervention for perinatal women.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Coaching
Description: Phone coaching calls occur weekly in conjunction with MomMoodBooster online modules.
Study: NCT05689372

Intervention type: DRUG
Intervention: Semaglutide
Description: Participants will receive Ozempic (solution for injection 1.34 mg/ml (Semaglutide s.c.) according to routine clinical practice conditions for 26 weeks. The physician will determine the dose of Ozempic in accordance with the K-PI.
Study: NCT06012916

Intervention type: DRUG
Intervention: Esketamine nasal spray
Description: This is an observational study. The Esketamine nasal spray is administered by the attending physician during a regular treatment appointment at the Interventional Psychiatry Clinic. Esketamine dosages may range between 28-84mg. The study does not interfere with the individual treatment plan in any way.
Study: NCT06057766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity tele coaching program
Description: The program includes~1. one-to-one semi-structured interview with the coach discussing the importance of physical activity, motivation, self-efficacy, barriers, favourite activities, and (coping) strategies to become more active resulting in an individual action plan;~2. step counter (Fitbit) providing direct feedback which automatically sends data to the smartphone via blue-tooth. Patients will be asked to wear this step counter every day during the intervention;~3. smartphone coaching application (mPAC), installed on a smartphone and linked to the step counter, will provide automated coaching by displaying an individual activity goal (expressed as daily step count) and daily and weekly feedback on the performance (steps) of the patient.~4. phone calls by the coaches initiated in pre-defined situations (non-compliance with wearing the step counter, failure to transmit the data, failure to progress).~Evidence-based behaviour change techniques will be implemented.
Study: NCT04760782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Description: Abaloparatide 80 mcg by subcutaneous, self-administered injection once per day (8 weeks)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hard collar immobilization
Description: Hard collar immobilization of the cervical spine for 12 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hard collar immobilization
Description: Hard collar immobilization of the cervical spine for 12 weeks
Study: NCT05159440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORL-2-307-MAB
Description: monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORL-2-307-MAB
Description: monoclonal antibody
Study: NCT05569408

Intervention type: DRUG
Intervention: EVUSHELD
Description: Tixagevimab (AZD8895) and cilgavimab (AZD1061)

Intervention type: DRUG
Intervention: EVUSHELD
Description: Tixagevimab (AZD8895) and cilgavimab (AZD1061)